2025 Disease Molecular Biology 
Drug Target Review
JUNE 5, 2025
Despite recent advances in gene therapy for sickle cell disease (SCD) , automated red blood cell exchange (aRBCX) remains a cornerstone therapy that plays a vital yet underutilised role in managing complications and enhancing quality of life for millions living with this devastating condition worldwide.
Drug Target Review
JULY 7, 2025
The FDA’s new roadmap In April 2025, the FDA announced a major regulatory shift with its plan to phase out the requirement for animal testing in the development of monoclonal antibodies and other drugs, when scientifically appropriate. This scarcity disrupts research timelines and limits the ability to replicate results across studies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Codon
JUNE 5, 2025
Gray, in London to discuss the significance of her recovery at the Third International Summit on Human Genome Editing , described Casgevy as “a new beginning for people with sickle cell disease.” ” Despite its association with genome editing, 1 CRISPR didn’t start out as a tool for fighting genetic disease.
Broad Institute
JUNE 25, 2025
By Allessandra DiCorato June 25, 2025 Credit: Xavier and Smillie labs Microscopy image shows intestinal tissue from a Crohn’s patient with fibrosis. In the new study, Xavier’s team analyzed 61 tissue samples from 21 patients with Crohn’s — from both routine biopsies and surgeries — and 10 people without inflammatory bowel disease.
Codon
JULY 21, 2025
There are signs that what we currently call “rheumatoid arthritis” may turn out to be more than one disease. There are other steps that might similarly advance biology into having the mechanical and predictive power of truly mature sciences, namely efforts to devise better tools and find principles free from exception.
Broad Institute
OCTOBER 16, 2024
Chan School of Public Health, lauded Studier for how the technology has enabled strategies for infectious disease control. Nominations for the 2025 Merkin Prize are now open and will close on December 6, 2024, at 11:59 p.m. For further information on how to nominate for the 2025 Merkin Prize, please visit the prize website.
Drug Target Review
JULY 1, 2024
As a non-NSAID, it reduces adverse effects associated with these pain relief drugs, including kidney injury, GI gastritis/ulceration and blood pressure elevation, which can affect patients with cardiovascular disease and the elderly. We set out to improve health by developing a novel non-opioid that avoids potential abuse.
Expert insights. Personalized for you.
Let's personalize your content